Celltrion acquires approval of ‘Herzuma’ in Europe

Published: 2018-02-20 14:41:54

Updated: 2018-02-20 14:41:54

Celltrion announced Herzuma(CT-P6, generic name: Trastuzumab), an antibody biosimilar for the treatment of breast cancer, acquired approval from the European Medicines Agency(EMA) on the 13^th(local time). The EMA gave the approval for the Herzuma’s entire indications, such as early breast cancer and metastatic breast cancer and metastatic stomach cancer.

Celltrion has once received an opinion ...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.